Tag: information

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

Dubai, June 26, 2026 (GLOBE NEWSWIRE) -- Reference is made to the announcement by Vantage Drilling International Ltd. (the “Company”) on 29 May 2026 regarding the proposed merger pursuant to which a wholly owned subsidiary of Eldorado Drilling AS is to merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Eldorado Drilling AS (the "Merger"). The Company is pleased to announce that all conditions to completion of the Merger are expected to be satisfied as of 1:00 PM ET on 26 June 2026, subject to continued satisfaction of customary closing conditions through to that time.

JACKSONVILLE, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers” or the “Company”) (NASDAQ: REG) will announce its second quarter 2026 earnings results on Wednesday, July 29, 2026, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Thursday, July 30, 2026, at 11:00 a.m. ET.

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.